Literature DB >> 6352727

Insulin-mediated glucose disposal in type I diabetes: evidence for insulin resistance.

S Del Prato, R Nosadini, A Tiengo, P Tessari, A Avogaro, R Trevisan, A Valerio, M Muggeo, C Cobelli, G Toffolo.   

Abstract

To clarify whether type I diabetes is characterized by insulin resistance, insulin-mediated glucose metabolism (M; milligrams per kg/min) was estimated by means of the glucose clamp technique in five insulin-dependent diabetic patients and six normal subjects. Three glucose clamps were carried out under different metabolic conditions. Free insulin plateaux were similar during each clamp in both groups. The first clamp was performed in normal subjects after an overnight fast [blood glucose, 80 +/- 3 mg/dl (mean +/- SEM)] and in diabetic patients 18 h after insulin withdrawal (blood glucose, 366 +/- 47 mg/dl). Diabetic patients had a M value (4.25 +/- 0.74) not different from normals (5.38 +/- 0.63; P = NS). The second clamp was done with the same glycemic values (approximately 125 mg/dl) in both groups. M increased to 8.07 +/- 1.06 (P less than 0.01) in the normal subjects and decreased to 2.87 +/- 0.50 (P = NS) in the diabetic patients. The M value in the diabetic patients was lower than that in the normal subjects (P less than 0.05). The third clamp was performed in three diabetic patients after 1 month of treatment with continuous sc insulin infusion. The mean blood glucose level was 88 +/- 6 mg/dl, and M was 3.23 +/- 0.38, significantly lower than that of the normal subjects in the basal state (P less than 0.05). No differences were found in insulin binding to erythrocytes. The mean plasma clearance rate (milliliters per m2/min) of free insulin was the same in both groups (428 +/- 113 in normal subjects and 354 +/- 83 in diabetic patients). Basal endogenous glucose production was higher in the diabetics (3.13 +/- 0.48 mg/kg X min) than in the normal subjects (1.71 +/- 0.57). During the clamp, however, endogenous glucose production was similarly inhibited (approximately 95%) in both groups. Multiple glucose clamp studies were also performed at three different insulin infusion rates (21, 73, and 760 mU/m2 X min, respectively) to generate an insulin-dose response curve for glucose disposal in six diabetic patients treated with continuous sc insulin infusion for at least 6 months. This allowed investigation of the effect of chronic strict insulin therapy leading to normal glucose and intermediary metabolite levels and identification of the cellular mechanism of insulin resistance. A significant reduction of the maximal glucose disposal rate (10.7 +/- 0.5 mg/kg X min) was found in these diabetic patients compared to that in normal subjects (14.9 +/- 1.0; P less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352727     DOI: 10.1210/jcem-57-5-904

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Expression of glycogen synthase and phosphofructokinase in muscle from type 1 (insulin-dependent) diabetic patients before and after intensive insulin treatment.

Authors:  H Vestergaard; P H Andersen; S Lund; P Vedel; O Pedersen
Journal:  Diabetologia       Date:  1994-01       Impact factor: 10.122

2.  Enhanced hepatic insulin sensitivity, but peripheral insulin resistance in patients with type 1 (insulin-dependent) diabetes.

Authors:  O Hother-Nielsen; O Schmitz; J Bak; H Beck-Nielsen
Journal:  Diabetologia       Date:  1987-11       Impact factor: 10.122

3.  Characterization of insulin resistance in type I diabetes.

Authors:  W Kerner; I Navascués; T von Schrenck; R Fussgänger; P Arias; E F Pfeiffer
Journal:  Klin Wochenschr       Date:  1985-06-18

4.  Assessment of insulin action in insulin-dependent diabetes mellitus using [6(14)C]glucose, [3(3)H]glucose, and [2(3)H]glucose. Differences in the apparent pattern of insulin resistance depending on the isotope used.

Authors:  P M Bell; R G Firth; R A Rizza
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

5.  Assessment of insulin sensitivity in adults with permanent neonatal diabetes mellitus due to mutations in the KCNJ11 gene encoding Kir6.2.

Authors:  Jan Skupien; Maciej T Malecki; Wojciech Mlynarski; Tomasz Klupa; Krzysztof Wanic; Agnieszka Gach; Iwona Solecka; Jacek Sieradzki
Journal:  Rev Diabet Stud       Date:  2006-05-10

6.  Impact of insulin deprivation and treatment on sphingolipid distribution in different muscle subcellular compartments of streptozotocin-diabetic C57Bl/6 mice.

Authors:  Piotr Zabielski; Agnieszka Blachnio-Zabielska; Ian R Lanza; Srinivas Gopala; S Manjunatha; Daniel R Jakaitis; Xuan-Mai Persson; Jaime Gransee; Katherine A Klaus; Jill M Schimke; Michael D Jensen; K Sreekumaran Nair
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-24       Impact factor: 4.310

7.  Hyperglucagonemia and insulin-mediated glucose metabolism.

Authors:  S Del Prato; P Castellino; D C Simonson; R A DeFronzo
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

8.  Insulin receptors on circulating blood cells from patients with pancreatogenic diabetes: a comparison with type I diabetes and normal subjects.

Authors:  M Muggeo; P Moghetti; P P Faronato; A Valerio; A Tiengo; S Del Prato; R Nosadini
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

9.  Defective suppression by insulin of leucine-carbon appearance and oxidation in type 1, insulin-dependent diabetes mellitus. Evidence for insulin resistance involving glucose and amino acid metabolism.

Authors:  P Tessari; R Nosadini; R Trevisan; S V De Kreutzenberg; S Inchiostro; E Duner; G Biolo; M C Marescotti; A Tiengo; G Crepaldi
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

10.  Insulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM).

Authors:  Hui-Yu Liu; Sophia Y Cao; Tao Hong; Jianmin Han; Zhenqi Liu; Wenhong Cao
Journal:  J Biol Chem       Date:  2009-08-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.